Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.

Kaur P, Chamberlin AR, Poulos TL, Sevrioukova IF.

J Med Chem. 2016 May 12;59(9):4210-20. doi: 10.1021/acs.jmedchem.5b01146. Epub 2015 Sep 24.

2.

A small molecule screen identifies a novel compound that induces a homeotic transformation in Hydra.

Glauber KM, Dana CE, Park SS, Colby DA, Noro Y, Fujisawa T, Chamberlin AR, Steele RE.

Development. 2015 Jun 1;142(11):2081. doi: 10.1242/dev.126235. No abstract available.

3.

Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.

Zhu J, Chen H, Guo XE, Qiu XL, Hu CM, Chamberlin AR, Lee WH.

Eur J Med Chem. 2015;96:196-208. doi: 10.1016/j.ejmech.2015.04.021. Epub 2015 Apr 9.

4.

Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.

Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EY, Lee WH.

Oncogene. 2015 Mar 5;34(10):1220-30. doi: 10.1038/onc.2014.67. Epub 2014 Mar 24.

5.

A small molecule screen identifies a novel compound that induces a homeotic transformation in Hydra.

Glauber KM, Dana CE, Park SS, Colby DA, Noro Y, Fujisawa T, Chamberlin AR, Steele RE.

Development. 2013 Dec;140(23):4788-96. doi: 10.1242/dev.094490. Erratum in: Development. 2015 Jun 1;142(11):2081.

6.

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.

Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, Qiu XL, Chen CF, Hu CM, Goldblatt E, Bhatia R, Chamberlin AR, Chen PL, Lee WH.

EMBO Mol Med. 2013 Mar;5(3):353-65. doi: 10.1002/emmm.201201760. Epub 2013 Jan 22.

7.

Improving the Fmoc Solid Phase Synthesis of the Cyclic Hexapeptide Complement C5a Antagonist, PMX205.

Delisle Milton RC, Milton SC, Chamberlin AR.

Int J Pept Res Ther. 2011 Dec;17(4):337-342.

8.
9.

Acyl-chain methyl distributions of liquid-ordered and -disordered membranes.

Mihailescu M, Vaswani RG, Jardón-Valadez E, Castro-Román F, Freites JA, Worcester DL, Chamberlin AR, Tobias DJ, White SH.

Biophys J. 2011 Mar 16;100(6):1455-62. doi: 10.1016/j.bpj.2011.01.035.

10.

Kaitocephalin antagonism of glutamate receptors expressed in Xenopus oocytes.

Limon A, Reyes-Ruiz JM, Vaswani RG, Chamberlin AR, Miledi R.

ACS Chem Neurosci. 2010 Mar 17;1(3):175-181.

11.

Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues.

Qiu XL, Li G, Wu G, Zhu J, Zhou L, Chen PL, Chamberlin AR, Lee WH.

J Med Chem. 2009 Mar 26;52(6):1757-67. doi: 10.1021/jm8015969.

12.

Stereoselective synthesis of chiral IBR2 analogues.

Qiu XL, Zhu J, Wu G, Lee WH, Chamberlin AR.

J Org Chem. 2009 Mar 6;74(5):2018-27. doi: 10.1021/jo802607f.

PMID:
19191556
13.

Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-kaitocephalin.

Vaswani RG, Limon A, Reyes-Ruiz JM, Miledi R, Chamberlin AR.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):132-5. doi: 10.1016/j.bmcl.2008.11.004. Epub 2008 Nov 6.

PMID:
19017555
14.

Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.

Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK.

J Pharmacol Exp Ther. 2008 Jun;325(3):893-901. doi: 10.1124/jpet.107.135103. Epub 2008 Mar 12.

15.

Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site.

Tappan E, Chamberlin AR.

Chem Biol. 2008 Feb;15(2):167-74. doi: 10.1016/j.chembiol.2008.01.005.

16.

Stereocontrolled total synthesis of (--)-kaitocephalin.

Vaswani RG, Chamberlin AR.

J Org Chem. 2008 Mar 7;73(5):1661-81. doi: 10.1021/jo702329z. Epub 2008 Jan 29.

PMID:
18225916
17.

Diastereoselective synthesis of glutamate-appended oxolane rings: synthesis of (s)-(+)-lycoperdic acid.

Cohen JL, Chamberlin AR.

J Org Chem. 2007 Nov 23;72(24):9240-7. Epub 2007 Nov 2.

PMID:
17975930
18.
19.

Pharmacophore identification: the case of the ser/thr protein phosphatase inhibitors.

Colby DA, Chamberlin AR.

Mini Rev Med Chem. 2006 Jun;6(6):657-65.

PMID:
16787376
20.

Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase.

Charvat TT, Lee DJ, Robinson WE, Chamberlin AR.

Bioorg Med Chem. 2006 Jul 1;14(13):4552-67. Epub 2006 Mar 9.

PMID:
16524737
21.

Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-dysiherbaine.

Cohen JL, Limon A, Miledi R, Chamberlin AR.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2189-94. Epub 2006 Feb 7.

PMID:
16455241
22.

A central strategy for converting natural products into fluorescent probes.

Alexander MD, Burkart MD, Leonard MS, Portonovo P, Liang B, Ding X, Joullié MM, Gulledge BM, Aggen JB, Chamberlin AR, Sandler J, Fenical W, Cui J, Gharpure SJ, Polosukhin A, Zhang HR, Evans PA, Richardson AD, Harper MK, Ireland CM, Vong BG, Brady TP, Theodorakis EA, La Clair JJ.

Chembiochem. 2006 Mar;7(3):409-16. No abstract available.

PMID:
16432909
23.

The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.

Esslinger CS, Agarwal S, Gerdes J, Wilson PA, Davis ES, Awes AN, O'Brien E, Mavencamp T, Koch HP, Poulsen DJ, Rhoderick JF, Chamberlin AR, Kavanaugh MP, Bridges RJ.

Neuropharmacology. 2005 Nov;49(6):850-61. Epub 2005 Sep 23.

PMID:
16183084
24.

Indole- and indoline-based kainate analogues with antagonist activity at ionotropic glutamate receptors.

Shou X, Miledi R, Chamberlin AR.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3942-7.

PMID:
16005214
25.

Fluorescent profiling of natural product producers.

Sandler JS, Fenical W, Gulledge BM, Chamberlin AR, La Clair JJ.

J Am Chem Soc. 2005 Jul 6;127(26):9320-1.

PMID:
15984830
26.

Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.

Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1969-73.

PMID:
15050639
27.

Microcystin analogues comprised only of Adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors.

Gulledge BM, Aggen JB, Eng H, Sweimeh K, Chamberlin AR.

Bioorg Med Chem Lett. 2003 Sep 1;13(17):2907-11.

PMID:
14611855
28.

Linearized and truncated microcystin analogues as inhibitors of protein phosphatases 1 and 2A.

Gulledge BM, Aggen JB, Chamberlin AR.

Bioorg Med Chem Lett. 2003 Sep 1;13(17):2903-6.

PMID:
14611854
29.

A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.

Colby DA, Liu W, Sheppeck JE, Huang HB, Nairn AC, Chamberlin AR.

Bioorg Med Chem Lett. 2003 May 5;13(9):1601-5.

PMID:
12699764
30.

The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.

Liu W, Sheppeck JE 2nd, Colby DA, Huang HB, Nairn AC, Chamberlin AR.

Bioorg Med Chem Lett. 2003 May 5;13(9):1597-600.

PMID:
12699763
31.

The microcystins and nodularins: cyclic polypeptide inhibitors of PP1 and PP2A.

Gulledgea BM, Aggena JB, Huangb HB, Nairnc AC, Chamberlin AR.

Curr Med Chem. 2002 Nov;9(22):1991-2003. Review.

PMID:
12369867
32.

The preparation of phenyl-stilbene derivatives using the safety catch linker.

Lew A, Chamberlin AR.

Methods Mol Biol. 2002;201:93-109. No abstract available.

PMID:
12357941
33.

Synthesis of DNA-binding polyamides. Robust solid-phase methods for coupling heterocyclic aromatic amino acids.

Krutzik PO, Chamberlin AR.

Methods Mol Biol. 2002;201:77-92. No abstract available.

PMID:
12357940
34.

Rapid solid-phase synthesis of DNA-binding pyrrole-imidazole polyamides.

Krutzik PO, Chamberlin AR.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2129-32.

PMID:
12127520
35.

Total synthesis of dysiherbaine.

Phillips D, Chamberlin AR.

J Org Chem. 2002 May 17;67(10):3194-201.

PMID:
12003525
36.

Increasing rates of reaction: microwave-assisted organic synthesis for combinatorial chemistry.

Lew A, Krutzik PO, Hart ME, Chamberlin AR.

J Comb Chem. 2002 Mar-Apr;4(2):95-105. Review. No abstract available.

PMID:
11886281
37.

Chemical Synthesis of Natural Product Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into Peptides.

Humphrey JM, Chamberlin AR.

Chem Rev. 1997 Oct 1;97(6):2243-2266. No abstract available.

PMID:
11848900
38.

Congener-independent immunoassay for microcystins and nodularins.

Fischer WJ, Garthwaite I, Miles CO, Ross KM, Aggen JB, Chamberlin AR, Towers NR, Dietrich DR.

Environ Sci Technol. 2001 Dec 15;35(24):4849-56.

PMID:
11775161
39.

Differing effects of substrate and non-substrate transport inhibitors on glutamate uptake reversal.

Anderson CM, Bridges RJ, Chamberlin AR, Shimamoto K, Yasuda-Kamatani Y, Swanson RA.

J Neurochem. 2001 Dec;79(6):1207-16.

40.
41.

Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters.

Koch HP, Kavanaugh MP, Esslinger CS, Zerangue N, Humphrey JM, Amara SG, Chamberlin AR, Bridges RJ.

Mol Pharmacol. 1999 Dec;56(6):1095-104.

PMID:
10570036
42.

Nontransportable inhibitors attenuate reversal of glutamate uptake in synaptosomes following a metabolic insult.

Koch HP, Chamberlin AR, Bridges RJ.

Mol Pharmacol. 1999 Jun;55(6):1044-8.

PMID:
10347246
43.
44.
45.

Structural determinants of substrates and inhibitors: probing glutamate transporters with 2,4-methanopyrrolidine-2,4-dicarboxylate.

Esslinger CS, Koch HP, Kavanaugh MP, Philips DP, Chamberlin AR, Thompson CM, Bridges RJ.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3101-6.

PMID:
9873684
46.

Design and synthesis of conformationally constrained inhibitors of high-affinity, sodium-dependent glutamate transporters.

Chamberlin AR, Koch HP, Bridges RJ.

Methods Enzymol. 1998;296:175-89. No abstract available.

PMID:
9779448
47.

Protein engineering with nonstandard amino acids.

Steward LE, Chamberlin AR.

Methods Mol Biol. 1998;77:325-54. Review. No abstract available.

PMID:
9770680
48.

Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins.

Sheppeck JE 2nd, Gauss CM, Chamberlin AR.

Bioorg Med Chem. 1997 Sep;5(9):1739-50. Review.

PMID:
9354230
49.

Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: enhanced excitotoxic potency and selectivity.

Willis CL, Dauenhauer DL, Humphrey JM, Chamberlin AR, Buller AL, Monaghan DT, Bridges RJ.

Toxicol Appl Pharmacol. 1997 May;144(1):45-55.

PMID:
9169068
50.

Supplemental Content

Loading ...
Support Center